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Fast and direct assessment of IgG galactosylation in serum 
 
  















APTS: 8-Aminopyrene-1,3,6-trisulfonic acid  
CE: capillary electrophoresis 
CE-LIF: Capillary electrophoresis – laser-induced fluorescence 
CRP: C-reactive protein 
CV: column volume 
EndoS: endo-β-N-acetyl-glucosaminidase S from Streptococcus pyogenes = 
Endoglycosidase S  
ESR: erythrocyte sedimentation rate 
GlcNAc: N-acetylglucosamine 
gp120: HIV envelope glycoprotein gp120 
HBV: Hepatitis B virus 
NAFLD: non-alcoholic fatty liver disease 
NASH: non-alcoholic steatohepatitis 
PNGaseF: Peptide N-glycosidase from Elizabethkingia meningoseptica (previously 
Flavobacterium meningosepticum) 
RA: rheumatoid arthritis 
ROC plot: Receiver Operating Characteristic plot 
TNF: tumor necrosis factor 
UGS: UnderGalactosylation Score 
UPLC: ultra-performance liquid chromatography 
 
  















Over the past 30 years, it has been firmly established that a wide spectrum of 
(autoimmune) diseases such as rheumatoid arthritis, Crohn’s and lupus, but also other 
pathologies like alcoholic and non-alcoholic steatohepatitis (ASH and NASH) are driven 
by chronic inflammation and are hallmarked by a reduced level of serum IgG 
galactosylation. IgG (under)galactosylation is a promising biomarker to assess disease 
severity, and monitor and adjust therapy. However, this biomarker has not been 
implemented in routine clinical chemistry due to a complex analytical procedure that 
necessitates IgG purification, which is difficult to perform and validate at high throughput. 
We addressed this issue by using endo-E-N-acetylglucosaminidase from Streptococcus 
pyogenes (endoS) to specifically release Fc N-glycans in whole serum. The entire assay 
can be completed in a few hours and only entails adding endoS and labeling the glycans 
with APTS. Glycans are then readily analyzed through capillary electrophoresis. We 
demonstrate in two independent patient cohorts that IgG undergalactosylation levels 
obtained with this assay correlate very well with scores calculated from PNGaseF-
released glycans of purified antibodies. Our new assay allows to directly and specifically 
measure the degree of IgG galactosylation in serum through a fast and completely liquid 
phase protocol, without the requirement for antibody purification. This should help 



















IgG glycosylation has been studied for more than 30 years, revealing how glycan 
composition is altered in patients suffering from chronic inflammatory diseases. Early 
studies showed that β-1,4-galactosylation on IgG glycans is lowered in individuals with 
rheumatoid arthritis (RA) or primary osteoarthritis (1, 2). Since then, other (chronic) 
inflammatory diseases have been shown to be associated with IgG undergalactosylation, 
including several cancers (3, 4), inflammatory bowel disease (5, 6), systemic lupus 
erythematosus (7) and liver disease (8–10). Remarkably, in RA and hepatitis B virus 
(HBV) patients, the glycosylation patterns normalize after treatment (11–13). IgG 
galactosylation can also differentiate between benign non-alcoholic fatty liver disease 
(NAFLD) and non-alcoholic steatohepatitis (NASH), a rapidly emerging disease (10). 
Many drugs for treatment of chronic inflammatory diseases are very expensive (e.g. anti-
TNF biologicals) and come with significant side effects. A biomarker for low grade chronic 
systemic inflammation and objective treatment monitoring would therefore contribute to 
improved clinical practice. 
Despite numerous publications presenting IgG undergalactosylation as a promising 
biomarker, current clinical tests for inflammation are largely limited to measuring C-
reactive protein (CRP) in serum or to historical tests such as the erythrocyte 
sedimentation rate (ESR). CRP levels fluctuate on a daily basis and it is therefore not a 
suitable marker for measuring chronic disease activity. ESR is a cheap test that is 
routinely conducted at high throughput, but requires fresh blood and is confounded by 
several interfering factors (14).  














Analyzing IgG glycosylation has so far not been feasible in routine clinical chemistry due 
to the complex and time consuming procedure that is required. Purifying the antibodies 
from patients’ sera is a prerequisite and is then usually followed by a denaturation step 
and PNGaseF deglycosylation to assess the sample N-glycosylation profile by MS, ultra-
performance liquid chromatography (UPLC) or capillary electrophoresis (CE) (15–17). 
The mandatory purification step is difficult to implement in routine testing and validation 
of antibody purity (which can affect the outcome of the test) at high throughput is 
cumbersome. Attempts to facilitate the purification process have recently resulted in an 
automated high-throughput IgG purification and N-glycan sample preparation platform 
(18). Although promising, sample turnaround for 96 samples takes at least 30 hours and 
requires an expensive robotic liquid handling and UPLC system, limiting its potential for 
clinical implementation. 
In 2001, Collin and Olsén (19) described an endo-β-N-acetylglucosaminidase secreted 
by the human pathogen Streptococcus pyogenes, designated endoS. EndoS likely 
suppresses host IgG effector functions, as it can deglycosylate native IgG. It hydrolyzes 
the N-glycan chitobiose core, leaving a single GlcNAc residue on the IgG heavy chain 
(20). The enzyme reportedly requires a natively folded IgG for its activity (21) and only 
cleaves Fc-linked glycans while leaving N-glycans on Fab and other proteins intact (22). 
Although it is generally accepted that endoS is specific for IgG Fc, activity towards HIV 
gp120 has been reported (23). Moreover, endoS specificity has never been tested in a 
complex mixture such as serum. Most Fc N-glycans are cleaved by endoS, although 
glycans with a bisecting GlcNAc have been shown to be resistant (24). The extent to 














which endoS-released glycans of patients’ sera resemble the total N-glycan profile of the 
corresponding purified antibodies remains unexplored. 
Here we describe a simple and fast, liquid phase, endoS-based assay to specifically 
measure IgG galactosylation without the need for antibody purification, which overcomes 
the main bottleneck for widespread clinical use of this biomarker. 
 
Experimental Procedures 
Materials: EndoS (IgGZERO™, Genovis) was reconstituted in ultrapure water at 20 U/μl. 
PNGaseF from Flavobacterium meningosepticum and sialidase from Arthrobacter 
ureafaciens were recombinantly produced as described previously (25). IgG, IgA and IgM 
from human serum (purity > 95%, Sigma-Aldrich) were reconstituted in PBS at 10 mg/ml 
(hereafter named ‘commercial IgG, IgA and IgM’).  
Patients and serum sampling: Serum samples from two independent cohorts (n(total) = 
188, NASH cohort (10), n = 96 and Hep0bster cohort (26), n = 92) in which patients were 
enlisted for bariatric surgery, were obtained from an outpatient clinic (Ghent University 
Hospital). Informed consent was given by all patients and the protocols were approved 
by the Hospital’s Ethics Committee. The study complies with the requirements of the 
Declaration of Helsinki. Blood was collected through classic venepuncture directly in 
serum preparation tubes (BD vacutainer SST tubes with silica clot activator and polymer 
gel). Serum was prepared according to the manufacturer’s instructions, aliquotted into 
standard eppendorfs and immediately stored in an internal biobank at -20°C or -80°C until 
the time of analysis. Patient data can be found in the Supplemental spreadsheet. 














IgG purification and serum IgG depletion: IgG from 30 μl aliquots of sera was purified 
using a Protein G Spin Plate for IgG Screening (Thermo Scientific) according to the 
manufacturer’s instructions. Samples were eluted in 420 μl of elution buffer and 
concentrated/buffer exchanged to 25 μl of PBS with 100 kDa cut-off Amicon® Ultra 
Centrifugal Filter Devices (Merck). A recovery of 83%, determined in a control experiment 
with pooled human IgG (commercial IgG), was used to set this 25 μl final buffer volume 
of the purified IgG. Purity and concentration of 12 IgG samples (6 randomly chosen from 
each cohort) were assessed by SDS-PAGE and A280 measurements to validate this 
purification procedure (data not shown). 
IgG-depleted sera were prepared with the ProteoPrep® Immunoaffinity Albumin and IgG 
Depletion Kit (Sigma-Aldrich) according to the manufacturer’s instructions. Depleted sera 
were concentrated/buffer-exchanged to PBS with 10 kDa cut-off Amicon® Centrifugal 
Filter devices to obtain original serum protein concentrations. 
Release of N-glycans: N-glycans were released with endoS or PNGaseF. For endoS 
catalyzed release, 2.5 μl of serum or purified IgG was incubated with 25 U of endoS for 
one hour at 37°C in a total volume of 10 μl in 150 mmol/L NaCl and 50 mmol/L Tris-HCl 
pH 8.5. 
For PNGaseF catalyzed N-glycan release, 3 μl of serum or purified IgG was denatured 
by incubation at 95°C for 5 minutes after adding 2 μl 50 mmol/L Tris-HCl pH 8.5 containing 
3.5% SDS. Samples were cooled and incubated for 1 hour at 37°C with 5 μl of 
deglycosylation mix, containing 11 mU PNGaseF in 50 mmol/L Tris-HCl pH 8.5 and 2% 
NP40. 














IgG specificity of endoS: To determine the protein specificity of endoS, serum and IgG-
depleted serum were incubated with 25 U of endoS for 1 hour at 37°C in buffers with a 
pH ranging from 5.0 to 9.0: 50 mmol/L NH4Ac (pH 5.0), MES (pH 6.0), sodium phosphate 
(pH 7.4) or Tris-Cl (pH 8.0, 8.5 and 9.0), each containing 150 mmol/L NaCl. 
IgA from patient samples was depleted/purified by diluting 500 μl plasma into 2 ml of PBS, 
followed by centrifugation at 16,000 x g and supernatant filtering (0.22 μM). The sample 
was then applied three times over 0.5 ml of PBS-equilibrated peptide M agarose 
(Invivogen). The flowthrough after the third pass was collected as IgA-depleted plasma.  
glycine pH 2.5 and neutralized with 2.5 ml of 1 M Tris-Cl pH 8.5.  
IgA and IgA-depleted plasma were buffer exchanged to 500 μl PBS with 3 and 30 kDa 
Amicon® centrifugal filter devices respectively.  
To determine whether endoS hydrolyses IgA or IgM glycans, 2.5 μl samples of 
commercial IgA, IgM, IgG, patient IgA and IgA-depleted plasma were digested with 25 U 
of endoS for 1 hour at 37°C in a total volume of 10 μl in 50 mmol/L NH4Ac pH 5.0 or 50 
mmol/L Tris-HCl pH 8.5, each with 150 mmol/L NaCl. 
Labelling and CE analysis: Released glycans were fluorescently labelled with APTS 
and analyzed by CE. Sample preparation, exoglycosidase digests (optional) and 
electrophoresis were performed as previously described (27). Briefly, 5 μl of labelling 
solution was added to an equal volume of crude digest or dry samples, followed by 
overnight incubation at 37°C. Excess label was removed by size-exclusion 
chromatography. Labelled N-glycans were then optionally desialylated, followed by CE 
on an ABI3130 DNA sequencer.  














Glycan symbolic representations are according to the Consortium for Functional 
Glycomics guidelines (28). Glycan structures, nomenclature and symbols are 
summarized in Supplemental Fig. 1.  
Experimental design and statistical rationale: The relevant peaks in the glycan profiles 
were quantified with GeneMapper® v3.7 (Applied Biosystems). The level of 
galactosylation (undergalactosylation score, UGS) from PNGaseF profiles was calculated 
as the ratio of NGA2F (G0F) glycan over the total peak height (Supplemental Fig. 2: 
PNGase UGS). The UGS from endoS profiles was calculated as the sum of peak heights 
of non-galactosylated glycans normalized to total peak height, taking into account the 
number of antennae for each glycan (Supplemental Fig. 2: endoS UGS).  
Statistical analyses were performed with R v3.4. The compound patient cohort (ntotal = 
188) was used in all analyses. Correlations between parameters were addressed with 
Pearson’s r. Outliers from linear regression were defined as having studentized residuals 




Assay and N-glycan profile characterization: To specifically analyze IgG N-
glycosylation in serum using endoS, we developed a new method (Fig. 1), based on 
procedures for profiling serum N-glycosylation that we previously optimized (25). In 
contrast to PNGaseF, which is commonly used to remove N-glycans from denatured 
proteins (Fig. 1, top), endoS activity requires native (dimeric) IgG Fc fragments (Fig. 1, 
bottom). Only N-glycans from IgG Fc are expected to be released by endoS while glycans 














released from the Fab fragment and other serum glycoproteins is undetectable, allowing 
the omission of IgG purification and denaturation steps. 
(Suggested location of Figure 1) 
To identify the glycan structures that are released by endoS, we analysed endoS-
released N-glycans from serum of a healthy individual and from IgG that was purified from 
the same serum sample (Fig. 2A and 2B). These CE profiles revealed the same six major 
glycan peaks and a few small peaks in both electropherograms. Some other very small 
peaks were only observed in the electropherogram from serum. These peaks are 
background peaks (they were also present in negative control experiments, in which the 
sample prep was performed without endoS, Supplemental Fig. 3). Each of these small 
peaks constitutes less than 1% of the total signal, and together they are less than 2-3% 
of the signal in a typical profile (Fig. 2A). Purified IgG, again from the same serum sample, 
was also digested with PNGaseF for full N-glycan profiling (Fig. 2C). Comparing digests 
on serum and IgG showed that endoS not only cleaves the same N-glycans in both 
samples, but we also observed similar relative peak heights (Fig. 2A and 2B). These first 
results indicated the feasibility of using endoS in serum for specific analysis of IgG 
glycosylation. 
Since endoS hydrolyses N-glycans in their chitobiose core, all the structures are truncated 
at the reducing end as compared to PNGaseF-released N-glycans, which hydrolyses the 
amide bond between the N-glycan and the asparagine side chain amine.  
The six major endoS-released N-glycan structures were confirmed with exoglycosidase 
digests and subsequent CE analysis of the resulting fragments (Supplemental Fig. 4). 
The N-glycans were all biantennary complex type N-glycans that are typically present on 














IgG Fc. We found no structures with bisecting GlcNAc, although about 10% of IgG Fc 
glycans are modified with such a structure (29). This is consistent with earlier reports that 
endoS does not hydrolyse glycans with a bisecting GlcNAc (24). 
To identify endoS resistant IgG glycans, an endoS digest was performed on commercial 
whole IgG, followed by separation of the Fab and Fc fragments and analysis of the 
remaining glycans on both (Supplemental Fig. 5). This revealed that Fc glycans with a 
bisecting GlcNAc (peaks indicated in red in Fig. 2C) indeed remain intact after endoS 
treatment. Bisialylated N-glycans (peaks indicated in green in Fig. 2C) are not released 
by endoS, but are originating almost exclusively from the Fab fragments (Supplemental 
Fig. 5), which are no substrate for endoS, as far as our methods can detect. The lack of 
bisialylated N-glycans in the endoS profiles is consistent with reports that less than 0.5% 
of Fc glycans are bisialylated (29). Taken together, these observations support the view 
that, when using purified IgG as the substrate, endoS is specific for the Fc portion. 
Glycans with a bisecting GlcNAc, which constitute about 10% of Fc glycans, are resistant 
to endoS hydrolysis. 
(Suggested location of Figure 2) 
IgG specificity of endoS in serum: To assess whether endoS cleaves only IgG N-
glycans in serum, we performed endoS digests on IgG-depleted serum. We previously 
demonstrated that up to 99% of IgG is removed by this procedure, without affecting other 
serum proteins (30). Treating fresh serum (or plasma) with endoS in different pH 
conditions (pH 5.0 – 9.0), revealed the release of an increasing amount of sialylated N-
glycans from proteins other than IgG with decreasing pH (Fig. 3A). Exoglycosidase 
digests showed these peaks to represent mono- and bisialylated, fully galactosylated 














biantennary complex type glycans. These glycans were not observed when using plasma 
or serum that had been freeze-thawed several times as the starting material (data not 
shown). Adding a physiological amount of commercial IgG (10 μg/μL) back to IgG-
depleted serum shows that non-IgG N-glycans are prominently present in the profiles at 
low pH, but not at high pH (Supplemental Fig. 6). 
Although endoS has been reported to be specific for IgG Fc, these experiments illustrate 
that this is only true at high pH. We speculated that the enzyme may recognize structurally 
similar protein substrates at suboptimal pH values. IgA and IgM are the two other 
immunoglobulins that are present in significant amounts in serum at about 2.5 μg/μl (IgA) 
and 1.5 μg/μl (IgM) (31). Moreover, the observed glycan types are typically abundantly 
present in IgA glycan profiles (32), but only at low levels in IgG profiles. Therefore, we 
assessed whether endoS can release IgA or IgM glycans at pH 5.0 and pH 8.5. We first 
confirmed the pH independence of IgG profiles and obtained identical profiles at pH 5.0 
or 8.5 (Fig. 3B). EndoS digests at pH 5.0 of IgA purified from a fresh patient plasma 
sample (Fig. 3C, left) produced the same two sialylated non-IgG glycans as in IgG-
depleted serum at pH 5.0. These glycans were absent in the profile of purified IgA 
digested at pH 8.5 (Fig. 3C, right). EndoS digests of commercial IgA gave the same result 
(data not shown). Similarly, endoS also produced minute amounts of the monosialylated 
N-glycan from IgM at pH 5.0 but not at pH 8.5 (Supplemental Fig. 7).  
To further investigate the contribution of IgA glycans, we compared the glycan profiles of 
fresh whole and IgA-depleted patient samples (Fig. 3D and 3E) at pH 5.0 and pH 8.5. 
Although completely removing IgA from the samples proved to be impossible even after 
several rounds of peptide M chromatography, a significant reduction in the peak height of 














the contaminating peaks in the pH 5.0 profile can be observed after IgA depletion. This 
indicates that these peaks are at least partially due to the presence of IgA. Taken 
together, these experiments indicate that the presence of other immunoglobulins does 
not interfere with the assay when working at a pH of 8.5 and that endoS is specific for IgG 
Fc glycans under these conditions and up to the limits of detection of the analytical 
techniques used. 
Further, we tested whether changing the incubation time, endoS concentration or 
incubation temperature influences the relative peak heights of the peaks used in the UGS 
calculation (and thus the calculated UGS) and found that the profile is dependent on these 
parameters only to a very small extent. Under the chosen assay conditions (pH 8.5, 37°C, 
25 units of endoS and 60 minutes of incubation time for 2.5 μl of serum), the UGS 
outcome is robust (Supplemental Fig. 8). 
As a final point, we also confirmed that, under the optimized assay conditions, the 
presence or absence of serum components does not influence the undergalactosylation 
score in a cohort of patients and healthy controls with a varying degree of IgG 
undergalactosylation. To do this, we compared endoS derived profiles from serum versus 
purified IgG for the total patient cohort. An almost perfect correlation (Fig. 3F; Pearson’s 
r = 0.986, p < 0.001) and a regression line with slope 0.982 and intercept at 0.019 
demonstrate that the calculated UGS is the same for serum and purified IgG, 
underscoring the reliability of the assay for use in serum under the selected conditions. 
(Suggested location of Figure 3) 
 














EndoS enables direct serum IgG galactosylation assessment: Classically, IgG Fc 
galactosylation levels have been determined through PNGaseF mediated deglycosylation 
of purified whole IgG. There seems to be no general consensus on the choice of glycans 
for calculating the level of galactosylation. Often, the peak height or area of NGA2F (also 
known as G0F, sometimes just G0) is used, most often normalized to the total signal or 
to the monogalactosylated glycan peak NG1A2F (G1F, sometimes G1) (33, 34). Another 
approach is to take the contribution of the galactosylation status of individual antennae 
on all glycans in the profile into account (35). In most cases, Fab fragment glycans also 
contribute to the calculation to some extent as PNGase is not specific for the Fc-linked N-
glycan. On the other hand, under the conditions of our assay, endoS specifically cleaves 
N-glycans from IgG Fc fragments and we cannot detect any release of Fab glycans. As 
a result, the measured undergalactosylation score (UGS) may not be exactly equal to that 
obtained from a PNGaseF digest. Given that only 15-25% of Fab fragments are 
glycosylated, they contribute much less to the total IgG glycan content than do Fc 
fragments (100% glycosylated). In other words, Fab glycosylation is not expected to be a 
major confounder. However, since the UGS calculated from endoS profiles is expected 
to be insensitive to Fab glycosylation, it should be an even better approach for 
determining UGS. For the comparisons presented here, we decided to use the G0F level 
normalized to the total glycan signal for PNGaseF derived profiles, as this appears to be 
the most commonly used way of calculating galactosylation levels (Supplemental Fig. 2). 
To assess the performance of our assay on patient serum samples, we analyzed IgG 
glycosylation in a total cohort of 188 patients and healthy controls with varying levels of 
galactosylation. We calculated the UGS from profiles obtained by either treating whole 














serum with endoS (and sialidase) or treating IgG purified from serum with PNGaseF and 
sialidase. We found a very good correlation between the two methods irrespective of the 
use of sialidase (Fig. 4A; no sialidase, Pearson’s r = 0.945, p < 0.001 and Fig. 4B; 
sialidase, Pearson’s r = 0.951, p < 0.001). 
Data points that we identified as outliers in a residuals analysis (studentized residuals > 
3) are indicated in red and represent the same samples in both experiments. Two outliers 
can be attributed to suboptimal IgG purification: the PNGaseF profiles from these samples 
contained relatively higher levels of triantennary glycan as compared to the rest of the 
cohort from which they were drawn (data not shown). Triantennary glycans are not 
present on IgG (36) and these glycans are thus considered to be an impurity from 
contaminating serum proteins. For these samples, it is likely that the UGS derived from 
PNGaseF profiles is incorrect. For the last outlier we found no straightforward 
explanation. 
Taken together, these strong correlations show that the galactosylation state of IgG in 
serum can be reliably measured with endoS, without the need for IgG purification. 
(Suggested location of Figure 4) 
To demonstrate the use of the assay for disease stage assessment of patients with 
chronic inflammatory disease, we analysed the subset of patients from the NASH cohort 
(n = 63), for whom histological liver data were available, which is needed for disease 
staging of chronic liver disease. We calculated the mean and 95% confidence intervals 
for the undergalactosylation scores in each group, both for PNGaseF-derived UGS from 
purified IgG (Figure 5A) and for endoS-derived UGS (no sialidase) from serum (Figure 
5B). In patients with histological features that indicate progression towards NASH, but no 














full fledged NASH yet (“borderline NASH”), a trend towards higher values is already 
noticeable. As demonstrated by ROC analysis (Figure 5C), endoS UGS (AUC = 0.819) 
can equally well distinguish NASH patients from non-NASH controls as PNGaseF derived 
UGS (AUC = 0.798).  
(Suggested location of Figure 5). 
 
Discussion 
In current clinical practice, inflammation is predominantly determined by measuring CRP 
values in serum. However, the short half-life (18 hours) of CRP cause fluctuations on a 
daily basis. Therefore, CRP is only suitable to assess acute inflammation. For ESR, which 
is frequently used in routine clinical chemistry, the most restricting limitation is that it 
requires fresh blood. Moreover, it has several analytical interferences that may confound 
the results (14). Hence, there is an unmet need for a marker that measures cumulative 
exposure to inflammation.  
Changes in IgG Fc glycosylation are uniquely suitable for monitoring chronic inflammation 
because IgG has a half-life of 24 days. The inflammatory processes that lead to IgG 
glycosylation changes need to persist for at least one to two t1/2 of the IgG pool to become 
noticeable. Since the first report in the context of RA in 1985 (1), many publications 
reported a decrease in IgG galactosylation in the vast majority of chronic necro-
inflammatory diseases (2–9) and recently very large studies have been reported on this 
glycosylation change (37, 38). In these same studies, increases in IgG Fc glycan core 
fucosylation have also been associated with increased chronic inflammation in the context 
of specific diseases (38). 














So far, all assays require IgG purification followed by complex analytics, making the 
biomarker rather unsuitable for routine clinical chemistry. 
Here we used endoglycosidase S from a pathogenic bacterium to cleave the N-glycans 
of IgG Fc. In this context, we should note that, due to the specific action of endoS, 
information on Fc glycan core fucosylation is lost, as this part of the glycan is left on the 
protein backbone. 
We show that, under optimized conditions, this enzyme is sufficiently specific that it can 
be used in a highly complex sample such as serum. We found that the enzyme’s 
specificity depends on the pH of the reaction buffer. In the pH range of 5.0-8.0, endoS is 
not entirely IgG specific, as it also releases some IgA N-glycans and minute amounts of 
IgM N-glycans. The specificity of endoS for IgG Fc drops with increasingly lower pH 
values of the buffer. However, under optimal conditions (at pH 8.5 or higher) we only 
detected glycans that were derived from IgG Fc fragments.  
Whole IgG UGS measurements by PNGaseF strongly rely on the purity of the IgG, which 
inherently is a potential problem during sample preparation. Moreover, since Fab and Fc 
glycans are distinct but overlapping, contribution of Fab N-glycans can never be 
completely excluded as a confounding factor, even when using purified IgG. Because of 
its specificity for IgG Fc under the assay conditions, UGS assessed by endoS should be 
more reliable than UGS from PNGaseF profiles of purified IgG. 
By comparing endoS profiles of serum and purified IgG in a cohort of patients and healthy 
controls, we confirmed that the outcome of the endoS-based assay is not dependent on 
the presence of other glycoproteins: we found an almost identical outcome for both 
methods. 














How does the fact that Fc glycans carrying a bisecting GlcNAc are resistant to endoS 
hydrolysis influence the outcome of our assay? Since these glycans are not part of the 
UGS calculations from endoS profiles, one might expect that they change the correlation 
between PNGaseF-based and endoS-based UGS calculations. However, IgG 
undergalactosylation of glycans with and without bisecting GlcNAc is strongly correlated 
so removing these glycans from the UGS determination does not change the validity of 
the assay method (Supplemental Fig.9). 
Our new endoS-based assay thus represents an important advance towards the clinical 
implementation of the well-studied IgG undergalactosylation as a correlate of chronic 
inflammation. It encompasses a fast and simple, Fc-glycan specific sample preparation 
and subsequent analysis on high-throughput CE analysers, e.g. on capillary DNA 
sequencers. The analytical step can also be readily adapted to cheap CE-based 
microfluidics platforms as we have shown before (25) and indeed, as we are currently 
working on for similar assays, on clinical CE analysers (39), paving the road for 
implementation in clinical chemistry routine. We envisage that this new assay will find use 
in diagnosis of the presence of chronic inflammation (e.g. as it accompanies the 
senescence processes associated with old age) and in monitoring of responses to anti-
inflammatory drug treatments. 
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Figure 1: Overview of the assay. In traditional PNGaseF-based assays to assess IgG 
Fc glycan galactosylation levels, IgG has to be purified from serum, denatured and then 
deglycosylated (and optionally desialylated) before the glycans can be analysed. We here 
propose a new assay, based on the use of endoS, in which the purification and 
denaturation steps can be omitted, as well as the use of sialidase. Due to endoS’ 
specificity for IgG Fc glycans on folded IgG, the resulting profile can be used to determine 
IgG Fc galactosylation levels. 
Figure 2: CE-LIF profiles of endoS and PNGaseF digested N-glycans. A) EndoS-
released N-glycans from serum of a healthy individual. B) EndoS-released N-glycans 
from purified whole IgG of the same individual. C) PNGaseF-released glycans from 
purified whole IgG of the same individual. Peaks in red represent the bisecting GlcNAc-
containing structures on the Fc fragment that are resistant to endoS hydrolysis. 
Bisialylated glycans and the bisected monosialylated N-glycan (indicated in green) are 
almost exclusively coming from Fab and were thus not hydrolysed by endoS (see 
Supplementary Figure 5 for additional data on the origin of the different glycan peaks). 
Figure 3: IgG specificity of EndoS in serum at different pH values. A) At pH values 
below 8.0, EndoS released bi- and monosialylated biantennary glycans from IgG-
depleted serum samples. These glycans were not released from IgG-depleted serum 
samples at pH values above 8. B) The relative peak heights in the N-glycan profile of 
commercial IgG (purity > 95%) were independent of the assay buffer. C)  Profiles of IgA, 
purified from patient samples. EndoS releases the same bi- and monosialylated 
biantennary N-glycans as found in IgG-depleted serum (Figure 3A) at pH 5.0. At pH 8.5, 














endoS does not hydrolyse any IgA glycans. D) Profiles of whole plasma from the same 
patient are pH dependent: at pH 8.5 a profile similar to the commercial IgG profile is 
observed. At pH 5.0, the profile contains IgG peaks as well as the same peaks as in the 
IgA profile and the depleted serum (Figure 3A and 3D). E) EndoS profiles of the same 
sample after IgA-depletion results similar profiles at either pH and also similar to the IgG 
profile. Note that 100 % IgA depletion is extremely difficult to achieve. Consequently, a 
small peak representing IgA-derived glycans can still be observed in the pH 5.0 profile of 
IgA-depleted samples. F) Serum and purified IgG from 188 patients and healthy controls 
were digested by endoS. The samples were labelled and analysed on an ABI3130 DNA 
sequencer. The UGS scores were calculated from the CE profiles. Scatterplots of 
undergalactosylation scores correlate very well for whole serum and IgG purified from the 
same serum samples, indicating that the presence of serum (glyco)proteins and other 
serum components do not change the assay outcome. 
Figure 4: Correlation between galactosylation levels calculated from serum derived 
profiles versus purified IgG derived profiles. Serum and purified IgG from 188 patients 
and healthy controls were digested by endoS or PNGaseF. The samples were labelled 
and analysed on an ABI3130 DNA sequencer. The UGS scores were calculated from the 
CE profiles. Scatterplots of undergalactosylation scores are shown for endoS profiles of 
serum versus PNGaseF derived profiles for purified IgG from the same serum samples. 
A) undergalactosylation scores calculated from endoS-derived profiles versus PNGaseF-
derived profiles. EndoS-derived glycans were not treated with sialidase. B) 
undergalactosylation scores calculated from endoS-derived profiles versus PNGaseF-
derived profiles. EndoS-derived glycans were treated with sialidase prior to analysis. 














Pearson's r correlation coefficients are shown in the right lower corner of all panels, along 
with p-values for each set. The linear regression lines (blue) with their 95% confidence 
intervals (grey) are also shown for each comparison. 
The three datapoints depicted in red were identified as outliers by studentized residuals 
> 3. Two out of these represent samples in which the IgG purification was suboptimal. 
Figure 5: Performance of the assay in NASH diagnosis. Based on the availability of 
histological data, 63 patients and healthy controls from the NASH cohort were selected 
for evaluation. Serum and purified IgG from these subjects were digested by endoS (no 
sialidase was added) or PNGaseF. The samples were labelled and analysed on a DNA 
sequencer and UGS scores were calculated from the CE profiles. A) 95% confidence 
intervals of the mean, derived from PNGaseF treated purified IgG. B) 95% confidence 
intervals of the mean, derived from endoS treated sera. For both experiments: n(healthy) = 
13, n(steatosis) = 22, n(borderline) = 10, n(NASH) = 18, n(total) = 63. C) A ROC curve analysis for 
the diagnosis of NASH (n = 18) versus healthy, steatosis and borderline NASH patients 
(n = 45).  
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